The Denmark-based pharmaceutical company said the “all-time high revenues” were largely because of its product sales. So far this year, more than 1 million people have received its Jynneos vaccine — the only approved monkeypox vaccine in the world — and Bavarian Nordic is working on “significant orders” for 2023.
In the first nine months of 2022, the drugmaker has made $1.86 billion in revenue, which is up 37 percent from last year’s figures.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.